Answer
The alendronate component of Fosavance inhibits osteoclast-mediated bone resorption without directly affecting bone formation, and bone formed during treatment is of normal quality.
Sources for this answer
- FOSAVANCE TabletsOrganon Pharma (UK) Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 25Document updated
Sources checked